Dr. Ghulam Surti
Claim this profileButler Hospital
Studies Alzheimer's Disease
Studies Dementia
3 reported clinical trials
6 drugs studied
Area of expertise
1Alzheimer's Disease
APP positive
PSEN1 positive
PSEN2 positive
2Dementia
APP positive
PSEN1 positive
PSEN2 positive
Affiliated Hospitals
Clinical Trials Ghulam Surti is currently running
Gantenerumab
for Alzheimer's Disease
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging. Stage 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD (e.g., CSF total tau, p-tau, NfL) compared to an external control group from the DIAN-OBS natural history study and the DIAN-TU-001 placebo-treated participants.
Recruiting0 awards Phase 2 & 310 criteria
Disease-Modifying Drugs
for Alzheimer's Disease
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.
Recruiting0 awards Phase 2 & 3
More about Ghulam Surti
Clinical Trial Related3 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Ghulam Surti has experience with
- E2814
- Gantenerumab
- Lecanemab
- Solanezumab
- Matching Placebo (E2814)
- Matching Placebo (Gantenerumab)
Breakdown of trials Ghulam Surti has run
Alzheimer's Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ghulam Surti specialize in?
Ghulam Surti focuses on Alzheimer's Disease and Dementia. In particular, much of their work with Alzheimer's Disease has involved APP positive patients, or patients who are PSEN1 positive.
Is Ghulam Surti currently recruiting for clinical trials?
Yes, Ghulam Surti is currently recruiting for 2 clinical trials in Providence Rhode Island. If you're interested in participating, you should apply.
Are there any treatments that Ghulam Surti has studied deeply?
Yes, Ghulam Surti has studied treatments such as E2814, Gantenerumab, Lecanemab.
What is the best way to schedule an appointment with Ghulam Surti?
Apply for one of the trials that Ghulam Surti is conducting.
What is the office address of Ghulam Surti?
The office of Ghulam Surti is located at: Butler Hospital, Providence, Rhode Island 02096 United States. This is the address for their practice at the Butler Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.